EDMONTON, Feb. 9, 2012 /CNW Telbec/ - Ceapro Inc. (TSXV: CZO) is pleased to announce that it has retained the services of Renmark
Financial Communications Inc. to handle its investor relations
"We are pleased with our achievements in building a solid and profitable
company over the last two years and are ready to get this success story
known. We are very pleased to announce that we have selected Renmark to
reinforce Ceapro's profile in the financial community and enhance the
visibility of our project portfolio. We choose Renmark because its
standards and methodologies fit best with the message we wish to
communicate to the investing public," noted Gilles Gagnon, Acting President & CEO of Ceapro Inc.
In consideration of the services to be provided, the Company has agreed
on a month to month agreement starting March 1st, 2012 paying a monthly retainer of $7,000 to Renmark Financial
Renmark Financial Communications does not have any interest, directly or
indirectly, in Ceapro Inc. or its securities, or any right or intent to
acquire such an interest.
About Ceapro Inc.
Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary
business activities relate to the development and commercialization of
natural products for personal care and cosmetic industries using
proprietary technology and natural, renewable resources. The commercial
line of natural active ingredients include beta glucan, avenanthamides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides. To learn more about Ceapro, visit www.ceapro.com
The TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Ceapro Inc.
For further information:
Chief Financial Officer
Telephone (Edmonton): (780) 917-8376